

NEVADA EHB BENCHMARK PLAN

SUMMARY INFORMATION

Plan Type	Plan from largest small group product, Point of Service
Issuer Name	Health Plan of Nevada, Inc.
Product Name	POS
Plan Name	Health Plan of Nevada Point Of Service Group 1 C XV 500 HCR
Supplemented Categories (Supplementary Plan Type)	Pediatric Oral (State CHIP)Pediatric Vision (FEDVIP)
Habilitative Services Included Benchmark (Yes/No)	No
Habilitative Services Defined by State (Yes/No)	Yes: Nevada will require habilitative services to be offered at parity with rehabilitative services.



BENEFITS AND LIMITS

Bene	fit Inf	ormation						General Information		
A Benefit	B EHB	C Benefit Description (may be the same as the Benefit name)	D Is the Benefit Covered?	E Quantitative Limit on Service?	F Limit Quantity	G Limit Unit and/or Description	H Minimum Stay	l Exclusions	J Explanations	K Additional Limitations or Restrictions?
Primary Care Visit to Treat an Injury or Illness	Yes	Primary care visit to treat an injury or illness	Covered	No					Benefits include allergy injections.	No
Specialist Visit	Yes	Specialist visit	Covered	No					Quantitative limit units apply, see EHB benchmark plan documents. Benefits include allergy injections.	No
Other Practitioner Office Visit (Nurse, Physician Assistant)	Yes	Doctors of Osteopathy, Dentistry, Podiatry and Chiropractors	Covered	No						No
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	Yes	Outpatient hospital facility and ambulatory surgical facility services	Covered	No						No
Outpatient Surgery Physician/Surgica I Services	Yes	Physician surgical services	Covered	No					Quantitative limit units apply, see EHB benchmark plan documents.	Yes
Hospice Services	Yes	Non-respite hospice care services	Covered	No					Quantitative limit units apply, see EHB benchmark plan documents.	Yes
Non-Emergency Care When Traveling Outside the U.S.			Not Covered							
Routine Dental Services (Adult)			Not Covered							
Infertility Treatment	Yes	Infertility services	Covered	Yes		Cycles per member per lifetime			Includes limited laboratory studies, diagnostic procedures, and infertility office visit evaluation.	No
Long- Term/Custodial Nursing Home Care			Not Covered							
Private-Duty Nursing	Yes	Private-duty nursing			30	Visits per year			Included within home health care services benefit.	No
Routine Eye Exam (Adult)		Hannah an C. 199	Not Covered							N
Urgent Care Centers or Facilities	Yes	Urgent care facility	Covered	No						No
Home Health Care Services	Yes	Home health care		Yes	30	Visits per year			Physician house calls, home care services and private duty nursing combined.	
Emergency Room Services	Yes	Emergency Room services	Covered	No						No



Bene	fit Inf	ormation						General Information		
A Benefit	B EHB	C Benefit Description (may be the same as	D Is the Benefit	E Quantitative Limit on	F Limit Quantity	G Limit Unit and/or	H Minimum Stay	l Exclusions	J Explanations	K Additional Limitations or
		the Benefit name)	Covered?	Service?		Description				Restrictions?
Emergency Transportation/ Ambulance	Yes	Ambulance services (air/ground)	Covered	No						No
Inpatient Hospital Services (e.g., Hospital Stay)	Yes	Inpatient hospital facility services	Covered	No						No
Inpatient Physician and Surgical Services	Yes	Physician surgical services	Covered	No					Quantitative limit units apply, see EHB benchmark plan documents.	Yes
Bariatric Surgery	Yes	Gastric restrictive surgery services	Covered	Yes	5000	Dollars per lifetime			For extreme obesity under the following circumstances: Have a body mass index (BMI) of greater than 40kg/m2; or have a BMI greater than 35kg/m2 with significant co-morbidities; and can provide documented evidence that dietary attempts at weight control are ineffective; and must be at least 18 years old. Attendance at a medically supervised weight loss program (within the last twenty-four (24) months) for at least three (3) months with documented failure of weight loss.	No
Cosmetic Surgery			Not Covered							
Skilled Nursing Facility	Yes	Skilled nursing facility	Covered	Yes	100	Days per year				No
Prenatal and Postnatal Care	Yes	Prenatal and postnatal	Covered	No						No
Delivery and All Inpatient Services for Maternity Care	Yes	Labor and delivery	Covered	No						No
Mental/Behavior al Health Outpatient Services	Yes	Mental health services	Covered	No						No
Mental/Behavior al Health Inpatient Services	Yes	Mental health services	Covered	No						No
Substance Abuse Disorder Outpatient Services	Yes	Substance abuse disorder	Covered	No						No
Substance Abuse Disorder Inpatient Services	Yes	Substance abuse disorder	Covered	No						No
Generic Drugs	Yes	Generic	Covered	Yes	30	Day supply per month			Mail order up to 90 day supply.	No
Preferred Brand Drugs	Yes	Preferred brand	Covered	Yes	30	Day supply per month			Mail order up to 90 day supply.	No
Non-Preferred Brand Drugs	Yes	Preferred brand	Covered	Yes	30	Day supply per month			Mail order up to 90 day supply.	No



Bene	fit Inf	ormation	General Information							
A Benefit	B EHB	(may be the same as the Benefit name)	Covered?	E Quantitative Limit on Service?	F Limit Quantity	Description	H Minimum Stay	l Exclusions	J Explanations	K Additional Limitations or Restrictions?
Specialty Drugs	Yes	Specialty	Covered	Yes		Day supply per month			Mail order up to 90 day supply.	No
Outpatient Rehabilitation Services	Yes	Short-term rehab services	Covered	Yes	60	Visits per year			Limit combined with inpatient Rehab.	No
Habilitation Services	Yes	Habilitation Services	Covered	No					\$36,000 per year for coverage of autism spectrum disorders	
Chiropractic Care	Yes	Chiropractic care	Covered	No					\$1,000 per member per CY and \$5,000 maximum lifetime benefit	No
Durable Medical Equipment	Yes	Durable medical equipment	Covered	Yes	4000	Dollars per lifetime				No
Hearing Aids	Yes	Hearing aids	Covered	No					\$5000 per year. Limited to a single purchase. Repairs and replacement limited to once every 3 years.	No
Diagnostic Test (X-Ray and Lab Work)	Yes	Laboratory services	Covered	No						No
Imaging (CT/PET Scans, MRIs)	Yes	Routine radiology and non-radiology diagnostic imaging services	Covered	No						No
Preventive Care/Screening/ Immunization	Yes	Preventive healthcare services	Covered	No						No
Routine Foot Care	Yes	Routine Foot Care	Covered	No						No
Acupuncture			Not Covered							
Weight Loss Programs			Not Covered							
Routine Eye Exam for Children	Yes	Routine eye exam	Covered	Yes	1	Visit per year				No
Eye Glasses for Children	Yes	Eye Glasses for Children	Covered	Yes	1	Pair of glasses (lenses and frames) per year				No
Dental Check-Up for Children	Yes	Periodic Oral examination	Covered	Yes	2	Visits per year			Limitations, including dollar limits, may apply, see EHB benchmark plan documents. Supplemented using NV CHIP.	No
Rehabilitative Speech Therapy	Yes	Rehabilitative Speech Therapy	Covered	No						No
Rehabilitative Occupational and Rehabilitative Physical Therapy	Yes	Rehabilitative Occupational and Rehabilitative Physical Therapy	Covered	No						No
Well Baby Visits and Care	Yes	Well Baby Visits and Care	Covered	No						No
Laboratory Outpatient and Professional Services	Yes	Laboratory Outpatient and Professional Services	Covered	No						No



Bene	fit Inf	ormation						General Information		
A Benefit	B EHB	(may be the same as	D Is the Benefit	E Quantitative Limit on	F Limit Quantity	G Limit Unit and/or	H Minimum Stay	l Exclusions	J Explanations	K Additional Limitations or
		the Benefit name)	Covered?	Service?		Description				Restrictions?
X-rays and Diagnostic Imaging	Yes	X-rays and Diagnostic Imaging	Covered	No						No
Basic Dental Care - Child	Yes	Basic Dental Care – Child	Covered	No					Limitations, including dollar limits, may apply, see EHB benchmark plan documents.	No
Orthodontia - Child	Yes	Orthodontia - Child	Covered	No					Limitations, including dollar limits, may apply, see EHB benchmark plan documents. Covered only if "medical need" conditions outlined in contract are met.	No
Major Dental Care - Child	Yes	Major Dental Care – Child	Covered	No					Limitations, including dollar limits, may apply, see EHB benchmark plan documents.	No
Basic Dental Care - Adult			Not Covered						·	
Orthodontia - Adult			Not Covered							
Major Dental Care – Adult			Not Covered							
Abortion for Which Public Funding is Prohibited			Not Covered							
Transplant	Yes	Transplant	Covered	Yes		Dollars of EME per transplant per benefit period			Quantitative limit units apply, see EHB benchmark plan documents. Transplant includes Organ and tissue transplant procurement.	No
Accidental Dental	Yes	Accidental Dental	Covered	No						No
Dialysis	Yes	Dialysis		No						No
Allergy Testing	Yes	Allergy Testing		No						No
Chemotherapy	Yes	Chemotherapy		No						No
Radiation	Yes	Radiation	Covered	No						No
Diabetes Education	Yes	Diabetes Education	Covered	No						No
Prosthetic Devices	Yes	Prosthetic Devices	Covered	Yes	10000	Dollars per lifetime per member			Prosthetic Devices includes Prosthetic and orthotic devices.	No
Infusion Therapy	Yes	Infusion Therapy	Covered	No						No
Treatment for Temporomandib ular Joint Disorders	Yes	Treatment for Temporomandibular Joint Disorders	Covered	Yes	2500	Dollars per calendar year, 4000 Dollars per lifetime			Quantitative limit units apply, see EHB benchmark plan documents.	No
Nutritional Counseling			Not Covered							
Reconstructive	Yes	Reconstructive	Covered							
Surgery	.,	Surgery								
Clinical Trials	Yes	Clinical Trials		No					Coverage for treatment received as part of a clinical trial or study.	No
Diabetes Care Management	Yes	Diabetes Care Management	Covered	No						No



Bene	efit Inf	ormation		General Information						
Α	В	С	D	E	F	G	Н	1	J	K
Benefit	EHB	Benefit Description	Is the	Quantitative	Limit	Limit Unit	Minimum	Exclusions	Explanations	Additional
		(may be the same as	Benefit	Limit on	Quantity	and/or	Stay			Limitations or
		the Benefit name)	Covered?	Service?		Description				Restrictions?
Inherited	Yes	Inherited Metabolic	Covered	No						No
Metabolic		Disorder – PKU								
Disorder – PKU										
Prescription	Yes	Prescription Drugs	Covered	No						No
Drugs Other		Other								



OTHER BENEFITS

Bene	fit Inf	ormation						General Information		
Α	В	С	D	Е	F	G	н	l l	J	К
Benefit	ЕНВ	Benefit Description	Is the	Quantitative	Limit	Limit Unit and/or		Exclusions	Explanations	Additional
		(may be the same as		Limit on	Quantity	•	Stay			Limitations or
		the Benefit name)	Covered?	Service?	,	•	,			Restrictions?
Inpatient respite	Yes	Inpatient respite	Covered	Yes	1500	Dollars per				No
services		services				member per CY.				
Outpatient	Yes	Outpatient respite	Covered	Yes	1000	Dollars per				No
respite services		services				member per CY.				
Hospice	Yes	Hospice	Covered	Yes	5	Visits per year			Treatment must be completed within 6 months of	Yes
bereavement		bereavement							the date of death.	
services		services								
Gastric restrictive	Yes	Gastric restrictive	Covered	Yes	5000	Dollars for all				No
surgery		surgery				complications in				
complications.		complications.				connection with				
						gastric restrictive				
						surgery.				
Organ and tissue	Yes	Organ and tissue	Covered	Yes	10000	Dollars per				No
transplant -		transplant - travel,				transplant per				
travel, lodging		lodging and meals				benefit period.				
and meals						·				
Organ and tissue	Yes	Organ and tissue	Covered	Yes	200	Dollars per day				No
transplant - daily		transplant - daily				. ,				
lodging and		lodging and meals								
meals										
Post-cataract	Yes	Post-cataract	Covered	Yes	100	Dollar maximum				No
surgical services,		surgical services,				frame or contact				
frames, lenses		frames, lenses and				lens allowance.				
and contacts		contacts								
Post-cataract	Yes	Post-cataract	Covered	Yes	1	Pair of glasses or				No
surgical services;		surgical services;				set of contact				
glasses and		glasses and contact				lenses as				
contact lenses		lenses				applicable per				
						member per				
						surgery.				
Coverage for	Yes	Coverage for autism	Covered	Yes	36000	Dollars per year for				No
autism spectrum		spectrum disorders				ABA.				
disorders										
Mastectomy	Yes	Mastectomy	Covered	No						No
reconstructive		reconstructive								
surgical services		surgical services								
Genetic disease	Yes	Genetic disease	Covered	No						No
testing services		testing services								
Medical supplies	Yes	Medical supplies	Covered	No					Medical Supplies are routine supplies that are	No
- x.c a.p.nee				-					customarily used during the course of treatment for	-
									an Illness or Injury.	
Other diagnostic	Yes	Other diagnostic and	Covered	No						No
and therapeutic		therapeutic services								1
services										
Special food	Yes	Special food	Covered	Yes	2500	Dollars per			Coverage for treatment of certain inherited	No
products		products	20.0.00	. 20		calendar year			metabolic diseases.	
F: - 2000	1	Jr 3400		1	1	1 ca.	L			1



PRESCRIPTION DRUG EHB-BENCHMARK PLAN BENEFITS BY CATEGORY AND CLASS

CATEGORY	CLASS	SUBMISSION COUNT
ANALGESICS	NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	20
ANALGESICS	OPIOID ANALGESICS, LONG-ACTING	11
ANALGESICS	OPIOID ANALGESICS, SHORT-ACTING	11
ANESTHETICS	LOCAL ANESTHETICS	3
ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS	ALCOHOL DETERRENTS/ANTI-CRAVING	3
ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS	OPIOID ANTAGONISTS	3
ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS	SMOKING CESSATION AGENTS	0
ANTI-INFLAMMATORY AGENTS	GLUCOCORTICOIDS	1
ANTI-INFLAMMATORY AGENTS	NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	20
ANTIBACTERIALS	AMINOGLYCOSIDES	8
ANTIBACTERIALS	ANTIBACTERIALS, OTHER	20
ANTIBACTERIALS	BETA-LACTAM, CEPHALOSPORINS	18
ANTIBACTERIALS	BETA-LACTAM, OTHER	5
ANTIBACTERIALS	BETA-LACTAM, PENICILLINS	11
ANTIBACTERIALS	MACROLIDES	5
ANTIBACTERIALS	QUINOLONES	8
ANTIBACTERIALS	SULFONAMIDES	4
ANTIBACTERIALS	TETRACYCLINES	4
ANTICONVULSANTS	ANTICONVULSANTS, OTHER	2
ANTICONVULSANTS	CALCIUM CHANNEL MODIFYING AGENTS	4
ANTICONVULSANTS	GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS	5
ANTICONVULSANTS	GLUTAMATE REDUCING AGENTS	3
ANTICONVULSANTS	SODIUM CHANNEL AGENTS	7
ANTIDEMENTIA AGENTS	ANTIDEMENTIA AGENTS, OTHER	1
ANTIDEMENTIA AGENTS	CHOLINESTERASE INHIBITORS	3
ANTIDEMENTIA AGENTS	N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST	1
ANTIDEPRESSANTS	ANTIDEPRESSANTS, OTHER	8
ANTIDEPRESSANTS	MONOAMINE OXIDASE INHIBITORS	4
ANTIDEPRESSANTS	SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS	9
ANTIDEPRESSANTS	TRICYCLICS	9
ANTIEMETICS	ANTIEMETICS, OTHER	10
ANTIEMETICS	EMETOGENIC THERAPY ADJUNCTS	8
ANTIFUNGALS	NO USP CLASS	25
ANTIGOUT AGENTS	NO USP CLASS	5
ANTIMIGRAINE AGENTS	ERGOT ALKALOIDS	2
ANTIMIGRAINE AGENTS	PROPHYLACTIC	4



ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMEPOLASTICS ALEVALTING AGENTS ANTINEOPLASTICS ANTINEO	CATEGORY	CLASS	SUBMISSION COUNT
ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMYCOBACTERIALS ANTIMEDPLASTICS ALEVATING AGENTS 6 ANTIMEDPLASTICS ALEVATING AGENTS 6 ANTIMEDPLASTICS ANTIMEDRASICS ANTIMEDPLASTICS ANTIMEDRASICS ANTI	ANTIMIGRAINE AGENTS	SEROTONIN (5-HT) 1B/1D RECEPTOR AGONISTS	7
ANTITUBERCULARS ANTITUBERCULARS ALKYLATING AGENTS ALKYLATING AGENTS ANTINEOPLASTICS ANTINEOPLASTICS ANTINEOPLASTICS ANTINEOPLASTICS ANTIESTROGENS/MODIFIERS 3 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 1 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 1 ANTINEOPLASTICS ANTIPARASTICS AN	ANTIMYASTHENIC AGENTS	PARASYMPATHOMIMETICS	3
ANTINEOPLASTICS ANTINGOGENIS ACTION OF ANTINEOPLASTICS ANTIPARASTICS ANTIP	ANTIMYCOBACTERIALS	ANTIMYCOBACTERIALS, OTHER	2
ANTINEOPLASTICS ANTIESTROGENS/MODIFIERS 3 ANTIESTROGENS/MODIFIERS 3 ANTINEOPLASTICS ANTIESTROGENS/MODIFIERS 3 ANTINEOPLASTICS ANTIMETABOLITES 2 ANTINEOPLASTICS ANTIMETABOLITES 2 ANTINEOPLASTICS ANTIMETABOLITES 3 ANTINEOPLASTICS ANTINEOPLASTICS ANTINEOPLASTICS 3 ANTINEOPLASTICS AROMATASE INHIBITORS, ARD GENERATION 3 ANTINEOPLASTICS ENZYME INHIBITORS 1 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MONOCLONAL ANTIBODIES 0 ANTINEOPLASTICS RETINOIDS 3 ANTIPARASTICS ANTIPEDATOZOALS 1 ANTIPARASTICS ANTIPEDATOZOALS 12 ANTIPARASTICS ANTIPEDATOZOALS 12 ANTIPARASTICS ANTIPARASTICS 12 ANTIPARASTICS PEDICULICIDES/SCABICIDES 5 ANTIPARARINSON AGENTS ANTIPARAMISON AGENTS, OTHER 3 ANTIPARAKINSON AGENTS ANTIPARAMISON AGENTS, OTHER 3 ANTIPARAKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARAKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARAKINSON AGENTS MONOAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARAMISON AGENTS MONOAMINE OXIDASE BE (MAO-B) INHIBITORS 2 ANTIPARAMISON AGENTS MONOAMINE OXIDASE BE (MAO-B) INHIBITORS 3 ANTIPARAMISON AGENTS MONOAMINE OXIDASE BE (MAO-B) INHIBITORS 3 ANTIPARAMISON AGENTS NO USP CLASS ANTI-INHIPAGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 5 INHIBITORS ANTIVIRALS ANTI-INHIPAGENTS, NUCLEOSIDE REVERSE TRANSCRIPTASE 5 INHIBITORS ANTIVIRALS ANTI-INHIPAGENTS, ONN-NUCLEOSIDE REVERSE TRANSCRIPTASE 5 INHIBITORS ANTI-INHIPAGENTS, ONN-NUCLEOSIDE REVERSE TRANSCRIPTASE 11 ANTIVIRALS ANTI-INHIPAGENTS, ONTO-INCLEOSIDE REVERSE TRANSCRIPTASE 11 ANTIVIRALS ANTI-INHIPAGENTS, ONTO-INCLEOSIDE REVERSE TRANSCRIPTASE	ANTIMYCOBACTERIALS	ANTITUBERCULARS	10
ANTINEOPLASTICS ANTIMETABOLITES 2 ANTIMEOPLASTICS ANTIMETABOLITES 2 ANTINEOPLASTICS ANTIMETABOLITES 2 ANTINEOPLASTICS ANTIMETABOLITES 3 ANTINEOPLASTICS ANTIMETABOLITES 3 ANTINEOPLASTICS ANTIMETABOLITES 3 ANTINEOPLASTICS ANTIMETABOLITES 3 ANTINEOPLASTICS ANTIMETABOLITES 1 ANTINEOPLASTICS AROMATASE INHIBITORS, SRD GENERATION 3 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MONOCLONAL ANTIBIODIES 0 ANTIPARASTICS RETINOIDS 3 ANTIPARASTICS RETINOIDS 3 ANTIPARASTICS ANTIPARASTICS 4 ANTIPARASTICS ANTIPARASTICS PEDICULICIDES 5 ANTIPARASTICS PEDICULICIDES/SCABICIDES 5 ANTIPARRINSON AGENTS ANTIPARRINSON AGENTS 3 ANTIPARRINSON AGENTS ANTIPARRINSON AGENTS 3 ANTIPARRINSON AGENTS ANTIPARRINSON AGENTS ANTIPARRINSON AGENTS DOPAMINE AGONISTS DOPAMINE AGONISTS 4 ANTIPARRINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARRINSON AGENTS MONOAMINE OXIDASE 8 (MAO-B) INHIBITORS 2 ANTIPARRINSON AGENTS MONOAMINE OXIDASE 8 (MAO-B) INHIBITORS 2 ANTIPARY ANTIPARAMINE AND AGENTS 10 ANTIPSYCHOTICS 12SI GENERATION/TYPICAL 9 ANTIPSYCHOTICS 12SI GENERATION/TYPICAL 9 ANTIPSYCHOTICS 12DI GENERATION/TYPICAL 9 ANTIPARASINAS 11DI AGENTS, NOUNCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTI-HIV AGENTS, NOUNCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTI-HIV AGENTS, NOUNCLEOSIDE AND NUCLEOTIDE REVERSE 11 ANTIPICALS ANTI-HIV AGENTS, NOUNCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTI-HIV AGENTS, NOUNCLEOSIDE AND NUCLEOTIDE REVERSE 11 ANTI-HIV AGENTS, NOUNCLEOSIDE AND NUCLEOTIDE REVERSE 1 ANTI-HIV AGENTS, NOUNCLEOSIDE AND NUCLEOTIDE REVERSE 1 ANTI-HIV AGENTS, NOUNCLEOSIDE AND NUCLEOTIDE REVE	ANTINEOPLASTICS	ALKYLATING AGENTS	6
ANTINEOPLASTICS ANTINETABOLITES 2 ANTINEOPLASTICS ANTINEOPLASTICS (SOUTH PR.) ANTINEOPLASTICS AROMATASE INHIBITORS, 3RD GENERATION 3 ANTINEOPLASTICS (SOUTH PR.) ANTIPARASTICS (SOUTH PR.)	ANTINEOPLASTICS	ANTIANGIOGENIC AGENTS	2
ANTINEOPLASTICS ANTINEOPLASTICS (ANTINEOPLASTICS) ANTINEOPLASTICS (ANDMATASE INHIBITORS, 3RD GENERATION 3 ANTINEOPLASTICS (ENZYME INHIBITORS) 1 ANTINEOPLASTICS (ANDMATASE INHIBITORS) 3 ANTIPARASITICS (ANTIPARASITICS) (ANTIPARASITICS) 4 ANTIPARASITICS (ANTIPARASITICS) (ANTIPARASITICS (ANTIPARASITICS) (ANTIPARASITICS) (ANTIPARASITICS (ANTIPARASITICS) (ANTIPARASITICS) (ANTIPARASITICS (ANTIPARASITICS) (ANTIPARASITICS) (ANTIPARASITICS (ARTIPARASITICS) (ANTIPARASITICS (ARTIPARASITICS) (ANTIPARASITICS (ARTIPARASITICS) (ANTI	ANTINEOPLASTICS	ANTIESTROGENS/MODIFIERS	3
ANTINEOPLASTICS AROMATASE INHIBITORS, 3RD GENERATION 3 ANTINEOPLASTICS ENZYME INHIBITORS 1 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MONOCLONAL ANTIBODIES 0 ANTINEOPLASTICS MONOCLONAL ANTIBODIES 0 ANTINEOPLASTICS RETINOIDS 3 ANTIPARASITICS ANTIPARASITICS 12 ANTIPARASITICS ANTIPARASITICS 12 ANTIPARASITICS ANTIPARASITICS 12 ANTIPARASITICS PEDICULCIDES/SCABICIDES 5 ANTIPARRINSON AGENTS ANTIPARRINSON AGENTS 3 ANTIPARRINSON AGENTS ANTIPARRINSON AGENTS 3 ANTIPARRINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARRINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARRINSON AGENTS MONOCAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPARRINSON AGENTS DOPAMINE OXIDASE B (MAO-B) INHIBITORS 10 ANTIPSYCHOTICS 15T GENERATION/TYPICAL 9 ANTIPSYCHOTICS 12ND GENERATION/TYPICAL 9 ANTIPSYCHOTICS	ANTINEOPLASTICS	ANTIMETABOLITES	2
ANTINEOPLASTICS ENZYME INHIBITORS 1 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 0 ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 0 ANTINEOPLASTICS RETINOIDS 3 ANTIPARASITICS ANTHELMINITICS 4 ANTHELMINITICS 4 ANTIPARASITICS ANTHELMINITICS 1 ANTIPARASITICS ANTIPARASITICS 5 ANTIPARASITICS PEDICULCIDES/SCABICIDES 5 ANTIPARKINSON AGENTS 5 ANTIPARKINSON AGENTS 3 ANTIPARKINSON AGENTS 3 ANTIPARKINSON AGENTS 3 ANTIPARKINSON AGENTS 3 ANTIPARKINSON AGENTS 4 ANTIPARKINSON AGENTS DOPAMINE PROLITSON STATE 3 ANTIPARKINSON AGENTS DOPAMINE PROLITSON STATE 3 ANTIPARKINSON AGENTS DOPAMINE PROLITSON STATE 3 ANTIPARKINSON AGENTS 1 ANTI	ANTINEOPLASTICS	ANTINEOPLASTICS, OTHER	3
ANTINEOPLASTICS MOLECULAR TARGET INHIBITORS 12 ANTINEOPLASTICS MONOCLONAL ANTIBODIES 0 ANTINEOPLASTICS RETINOIDS 3 ANTIPARASTICS ANTHELMINTICS 4 ANTIPARASTICS ANTIPARASTICS 12 ANTIPARASTICS ANTIPARASTICS 5 ANTIPARASTICS ANTIPARASTICS 12 ANTIPARASTICS ANTIPARASTICS 9 PEDICULICIDES/SCABICIDES 5 ANTIPARKINSON AGENTS 3 ANTIPARKINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS 3 ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS 4 ANTIPARKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPARY CHOICS 1ST GENERATION/TYPICAL 10 ANTIPSYCHOTICS 2ND GENERATION/ATYPICAL 9 ANTIPSYCHOTICS 15T GEN	ANTINEOPLASTICS	AROMATASE INHIBITORS, 3RD GENERATION	3
ANTINEOPLASTICS MONOCLONAL ANTIBODIES 0 ANTINEOPLASTICS RETINOIDS 3 ANTIBOPLASTICS ANTIBOPLASTICS ANTIBODIES 4 ANTIPARASITICS ANTIPROTOZOALS 12 ANTIPARASITICS PEDICULICIDES/SCABICIDES 5 ANTIPARASITICS PEDICULICIDES/SCABICIDES 5 ANTIPARRINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS 4 ANTIPARKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPSYCHOTICS 1ST GENERATION/ATYPICAL 9 ANTIPSYCHOTICS 1ST GENERATION/ATYPICAL 9 ANTIPSYCHOTICS TREATMENT-RESISTANT 1 ANTIPSYCHOTICS TREATMENT-RESISTANT 1 ANTIPSYCHOTICS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 5 INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTIVIRALS ANTI-HIV AGENTS, NON-BUCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-HIPATABE AGENTS 4 ANTI-HIPATABE AGENTS 4 ANTIVIRALS ANTI-HIPATABE AGENTS 4 ANTI-HIPATABE AGENTS 12 ANTIVIRALS ANTI-HIPATABE AGENTS 12	ANTINEOPLASTICS	ENZYME INHIBITORS	1
ANTINEOPLASTICS RETINOIDS 3 ANTIPARASTITICS ANTHELMINTICS 4 ANTIPARASTITICS ANTHELMINTICS 12 ANTIPARASTITICS PEDICULICIDES/SCABICIDES 5 ANTIPARASTITICS PEDICULICIDES/SCABICIDES 5 ANTIPARKINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS, OTHER 3 ANTIPARKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPSYCHOTICS 1ST GENERATION/TYPICAL 10 ANTIPSYCHOTICS 1ST GENERATION/TYPICAL 9 ANTIPSYCHOTICS TREATMENT-RESISTANT 11 ANTISPASTICITY AGENTS NO USP CLASS 5 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 15 INHIBITORS ANTI-HIV AGENTS, NULLEOSIDE AND NUCLEOTIDE REVERSE 11 ANTIVIRALS ANTI-HIV AGENTS, NULLEOSIDE AND NUCLEOTIDE REVERSE 11 ANTIVIRALS ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, OTHER 4 ANTI-HIV AGENTS, OTHER 4 ANTI-HIV AGENTS, OTHER 5 ANTI-HIV AGENTS 5 ANTI-HIV	ANTINEOPLASTICS	MOLECULAR TARGET INHIBITORS	12
ANTIPARASITICS ANTIPARASITICS (ANTIPROTOZOALS 12 ANTIPARASITICS (ANTIPROTOZOALS 12 ANTIPARASITICS (ANTIPROTOZOALS 5 ANTIPARASITICS (ANTIPARASITICS 5 ANTIPARASITICS (ANTIPARASITICS 5 ANTIPARASITICS (ANTIPARASITICS 5 ANTIPARKINSON AGENTS (ANTIPARKINSON AGENTS 6 ANTIPARKINSON AGENTS (ANTIPARKINSON AGENTS, OTHER 3 ANTIPARKINSON AGENTS (ANTIPARKINSON AGENTS 5 ANTIPARKINSON AGENTS (ANTIPARKINSON AGENTS 6 ANTIPARKINSON AGENTS (ANTIPARKINSON AGENTS 6 ANTIPARKINSON AGENTS (ANTIPARKINSON AGENTS 7 ANTIPARKINSON AGENTS (AN	ANTINEOPLASTICS	MONOCLONAL ANTIBODIES	0
ANTIPARASITICS ANTIPARASITICS PEDICULCIDES/SCABICIDES 5 ANTIPARKINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS, OTHER 3 ANTIPARKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARKINSON AGENTS MONOAMINE OXIDASE 8 (MAO-8) INHIBITORS 2 ANTIPSYCHOTICS 15T GENERATION/TYPICAL 10 ANTIPSYCHOTICS 2ND GENERATION/ATYPICAL 9 ANTIPSYCHOTICS 1REATMENT-RESISTANT 1 ANTISPASTICITY AGENTS NO USP CLASS 5 ANTI-VITOMEGALOVIRUS (CMV) AGENTS 4 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 1 ANTIVIRALS ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, OTHER 3 ANTIVIRALS ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIPLENZA AGENTS 4 ANTI-HIPLENZA AGENTS 12 ANTIVIRALS ANTI-HIPLENZA AGENTS 12 ANTIVIRALS ANTI-HEPATITIS AGENTS 12 ANTIVIRALS ANTIHEPATITIS AGENTS 16	ANTINEOPLASTICS	RETINOIDS	3
ANTIPARASITICS PEDICULICIDES/SCABICIDES 5 ANTIPARKINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTICHOLINERGICS 3 ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS 2 ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPSYCHOTICS 1ST GENERATION/TYPICAL 10 ANTIPSYCHOTICS 2ND GENERATION/ATYPICAL 9 ANTIPSYCHOTICS 1REATMENT-RESISTANT 1 ANTISPASTICITY AGENTS NO USP CLASS 5 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 5 ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 1 ANTIVIRALS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE 11 TRANSCRIPTASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 12 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 14 ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 14 ANTIVIRALS ANTI-HIV AGENTS AGENTS 12 ANTIVIRALS ANTI-HIPLENZA AGENTS 12	ANTIPARASITICS	ANTHELMINTICS	4
ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS DOPAMINE AGONISTS ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPASTICITY AGENTS ANTIVIRALS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS AN	ANTIPARASITICS	ANTIPROTOZOALS	12
ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS DOPAMINE AGONISTS 4 ANTIPARKINSON AGENTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS ANTIPSYCHOTICS ANTIPSYCHOTICS SIT GENERATION/TYPICAL ANTIPSYCHOTICS ANTIPSYCHOTICS TREATMENT-RESISTANT TREATMENT-RESISTANT TREATMENT-RESISTANT ANTIVIRALS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTI-CYTOMEGALOVIRUS (CMO-CYTOMEGALOVIRUS (CMV) AGENTS ANTI-CYTOMEGALOVIRUS (CMO-CYTOMEGALOVIRUS (CMV) AGENTS ANTI-CYTOMEGALOVIRUS (CMO-CYTOMEGALOVIRUS (CMO-CYTOMEGALO	ANTIPARASITICS	PEDICULICIDES/SCABICIDES	5
ANTIPARKINSON AGENTS DOPAMINE AGONISTS DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPSYCHOTICS 1ST GENERATION/TYPICAL 10 ANTIPSYCHOTICS 2ND GENERATION/ATYPICAL 9 ANTIPSYCHOTICS TREATMENT-RESISTANT 11 ANTISPASTICITY AGENTS NO USP CLASS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, ONTHER ANTIVIRALS ANTI-HIV AGENTS, ONTHER ANTI-HIV AGENTS, ONTHER ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIP AGENTS	ANTIPARKINSON AGENTS	ANTICHOLINERGICS	3
ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPARKINSON AGENTS ANTIPSYCHOTICS TREATMENT-RESISTANT NO USP CLASS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, NOTHER ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTI-HIV AGENTS	ANTIPARKINSON AGENTS	ANTIPARKINSON AGENTS, OTHER	3
ANTIPARKINSON AGENTS MONOAMINE OXIDASE B (MAO-B) INHIBITORS 2 ANTIPSYCHOTICS 1ST GENERATION/TYPICAL 10 ANTIPSYCHOTICS 2ND GENERATION/ATYPICAL 9 ANTIPSYCHOTICS ANTIPSYCHOTICS TREATMENT-RESISTANT 1 ANTISPASTICITY AGENTS NO USP CLASS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTI-HIV AGENTS ANTI-HIV AGENTS	ANTIPARKINSON AGENTS	DOPAMINE AGONISTS	4
ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS ANTIPSYCHOTICS TREATMENT-RESISTANT ANTISPASTICITY AGENTS NO USP CLASS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS ANTIVIRALS ANTI-HIV AGENTS ANTI-HIV AGENTS ANTIVIRALS ANTI-HIV AGENTS	ANTIPARKINSON AGENTS	DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS	2
ANTIPSYCHOTICS ANTIPSYCHOTICS TREATMENT-RESISTANT ANTISPASTICITY AGENTS NO USP CLASS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS ANTI-HIV AGE	ANTIPARKINSON AGENTS	MONOAMINE OXIDASE B (MAO-B) INHIBITORS	2
ANTIPSYCHOTICS TREATMENT-RESISTANT 1 ANTISPASTICITY AGENTS NO USP CLASS 5 ANTIVIRALS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-HIV AGENTS	ANTIPSYCHOTICS	1ST GENERATION/TYPICAL	10
ANTISPASTICITY AGENTS ANTI-CYTOMEGALOVIRUS (CMV) AGENTS ANTIVIRALS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIV AGENTS 4 ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIV AGENTS ANTI-HIV AGENTS 4 ANTI-HIV AGENTS	ANTIPSYCHOTICS	2ND GENERATION/ATYPICAL	9
ANTIVIRALS ANTI-YTOMEGALOVIRUS (CMV) AGENTS ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 4 ANTI-HIV AGENTS AN	ANTIPSYCHOTICS	TREATMENT-RESISTANT	1
ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE 11 TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, OTHER 3 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTI-INFLUENZA AGENTS 4 ANTI-INFLUENZA AGENTS 12 ANTIVIRALS ANTI-INFLUENZA AGENTS 6	ANTISPASTICITY AGENTS	NO USP CLASS	5
INHIBITORS ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI-HIV AGENTS, OTHER ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTI-HIV AGENTS	ANTIVIRALS	ANTI-CYTOMEGALOVIRUS (CMV) AGENTS	4
TRANSCRIPTASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS, OTHER ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS ANTIVIRALS ANTI-HIV AGENTS ANTI-HI	ANTIVIRALS		5
ANTIVIRALS ANTI-HIV AGENTS, PROTEASE INHIBITORS 9 ANTIVIRALS ANTI-INFLUENZA AGENTS 4 ANTIVIRALS ANTIHEPATITIS AGENTS 12 ANTIVIRALS ANTIHERPETIC AGENTS 6	ANTIVIRALS	·	11
ANTIVIRALS ANTI-INFLUENZA AGENTS 4 ANTIVIRALS ANTIHEPATITIS AGENTS 12 ANTIVIRALS ANTIHERPETIC AGENTS 6	ANTIVIRALS	ANTI-HIV AGENTS, OTHER	3
ANTIVIRALS ANTIHEPATITIS AGENTS 12 ANTIVIRALS ANTIHERPETIC AGENTS 6	ANTIVIRALS	ANTI-HIV AGENTS, PROTEASE INHIBITORS	9
ANTIVIRALS ANTIHERPETIC AGENTS 6	ANTIVIRALS	ANTI-INFLUENZA AGENTS	4
	ANTIVIRALS	ANTIHEPATITIS AGENTS	12
ANYIOLYTICS OTHER 4	ANTIVIRALS	ANTIHERPETIC AGENTS	6
ANAIOLITICS, OTHER	ANXIOLYTICS	ANXIOLYTICS, OTHER	4



CATEGORY	CLASS	SUBMISSION COUNT
ANXIOLYTICS	SSRIS/SNRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITORS/SEROTONIN	5
	AND NOREPINEPHRINE REUPTAKE INHIBITORS)	
BIPOLAR AGENTS	BIPOLAR AGENTS, OTHER	6
BIPOLAR AGENTS	MOOD STABILIZERS	5
BLOOD GLUCOSE REGULATORS	ANTIDIABETIC AGENTS	21
BLOOD GLUCOSE REGULATORS	GLYCEMIC AGENTS	2
BLOOD GLUCOSE REGULATORS	INSULINS	8
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	ANTICOAGULANTS	7
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	BLOOD FORMATION MODIFIERS	8
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	COAGULANTS	1
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	PLATELET MODIFYING AGENTS	7
CARDIOVASCULAR AGENTS	ALPHA-ADRENERGIC AGONISTS	5
CARDIOVASCULAR AGENTS	ALPHA-ADRENERGIC BLOCKING AGENTS	4
CARDIOVASCULAR AGENTS	ANGIOTENSIN II RECEPTOR ANTAGONISTS	8
CARDIOVASCULAR AGENTS	ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS	10
CARDIOVASCULAR AGENTS	ANTIARRHYTHMICS	10
CARDIOVASCULAR AGENTS	BETA-ADRENERGIC BLOCKING AGENTS	13
CARDIOVASCULAR AGENTS	CALCIUM CHANNEL BLOCKING AGENTS	9
CARDIOVASCULAR AGENTS	CARDIOVASCULAR AGENTS, OTHER	4
CARDIOVASCULAR AGENTS	DIURETICS, CARBONIC ANHYDRASE INHIBITORS	2
CARDIOVASCULAR AGENTS	DIURETICS, LOOP	4
CARDIOVASCULAR AGENTS	DIURETICS, POTASSIUM-SPARING	4
CARDIOVASCULAR AGENTS	DIURETICS, THIAZIDE	6
CARDIOVASCULAR AGENTS	DYSLIPIDEMICS, FIBRIC ACID DERIVATIVES	2
CARDIOVASCULAR AGENTS	DYSLIPIDEMICS, HMG COA REDUCTASE INHIBITORS	7
CARDIOVASCULAR AGENTS	DYSLIPIDEMICS, OTHER	6
CARDIOVASCULAR AGENTS	VASODILATORS, DIRECT-ACTING ARTERIAL	3
CARDIOVASCULAR AGENTS	VASODILATORS, DIRECT-ACTING ARTERIAL/VENOUS	3
CENTRAL NERVOUS SYSTEM AGENTS	ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES	4
CENTRAL NERVOUS SYSTEM AGENTS	ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, NON-	4
	AMPHETAMINES	
CENTRAL NERVOUS SYSTEM AGENTS	CENTRAL NERVOUS SYSTEM AGENTS, OTHER	4
CENTRAL NERVOUS SYSTEM AGENTS	FIBROMYALGIA AGENTS	3
CENTRAL NERVOUS SYSTEM AGENTS	MULTIPLE SCLEROSIS AGENTS	6
DENTAL AND ORAL AGENTS	NO USP CLASS	7
DERMATOLOGICAL AGENTS	NO USP CLASS	35
ENZYME REPLACEMENT/MODIFIERS	NO USP CLASS	17
GASTROINTESTINAL AGENTS	ANTISPASMODICS, GASTROINTESTINAL	6



CATEGORY	CLASS	SUBMISSION COUNT
GASTROINTESTINAL AGENTS	GASTROINTESTINAL AGENTS, OTHER	7
GASTROINTESTINAL AGENTS	HISTAMINE2 (H2) RECEPTOR ANTAGONISTS	4
GASTROINTESTINAL AGENTS	IRRITABLE BOWEL SYNDROME AGENTS	2
GASTROINTESTINAL AGENTS	LAXATIVES	3
GASTROINTESTINAL AGENTS	PROTECTANTS	2
GASTROINTESTINAL AGENTS	PROTON PUMP INHIBITORS	6
GENITOURINARY AGENTS	ANTISPASMODICS, URINARY	7
GENITOURINARY AGENTS	BENIGN PROSTATIC HYPERTROPHY AGENTS	9
GENITOURINARY AGENTS	GENITOURINARY AGENTS, OTHER	3
GENITOURINARY AGENTS	PHOSPHATE BINDERS	3
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING	GLUCOCORTICOIDS/MINERALOCORTICOIDS	23
(ADRENAL)		
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING	NO USP CLASS	3
(PITUITARY)		
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING	NO USP CLASS	1
(PROSTAGLANDINS)		
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	ANABOLIC STEROIDS	2
HORMONES/MODIFIERS)		
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	ANDROGENS	4
HORMONES/MODIFIERS)		
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	ESTROGENS	6
HORMONES/MODIFIERS)	PROCECTING	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	PROGESTINS	4
HORMONES/MODIFIERS) HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	SELECTIVE ESTROGEN RECEPTOR MODIFYING AGENTS	1
HORMONES/MODIFIERS)	SELECTIVE ESTROGEN RECEPTOR MODIFTING AGENTS	1
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)	NO LISP CLASS	3
HORMONAL AGENTS, STIMOLANT/REI LACEMENT/MODIT TING (TTTROID)	NO USP CLASS	1
HORMONAL AGENTS, SUPPRESSANT (PARATHYROID)	NO USP CLASS	1
HORMONAL AGENTS, SUPPRESSANT (PITUITARY)	NO USP CLASS	7
HORMONAL AGENTS, SUPPRESSANT (SEX HORMONES/MODIFIERS)	ANTIANDROGENS	5
HORMONAL AGENTS, SUPPRESSANT (THYROID)	ANTITHYROID AGENTS	2
IMMUNOLOGICAL AGENTS	IMMUNE SUPPRESSANTS	21
IMMUNOLOGICAL AGENTS	IMMUNIZING AGENTS, PASSIVE	0
IMMUNOLOGICAL AGENTS	IMMUNOMODULATORS	10
INFLAMMATORY BOWEL DISEASE AGENTS	AMINOSALICYLATES	3
INFLAMMATORY BOWEL DISEASE AGENTS INFLAMMATORY BOWEL DISEASE AGENTS	GLUCOCORTICOIDS	5
INFLAMMATORY BOWEL DISEASE AGENTS INFLAMMATORY BOWEL DISEASE AGENTS	SULFONAMIDES	1
METABOLIC BONE DISEASE AGENTS	NO USP CLASS	15
INICIADOLIC DOINE DISEASE AGENTS	NO UJF CLAJJ	13



CATEGORY	CLASS	SUBMISSION COUNT
OPHTHALMIC AGENTS	OPHTHALMIC PROSTAGLANDIN AND PROSTAMIDE ANALOGS	3
OPHTHALMIC AGENTS	OPHTHALMIC AGENTS, OTHER	4
OPHTHALMIC AGENTS	OPHTHALMIC ANTI-ALLERGY AGENTS	9
OPHTHALMIC AGENTS	OPHTHALMIC ANTI-INFLAMMATORIES	11
OPHTHALMIC AGENTS	OPHTHALMIC ANTIGLAUCOMA AGENTS	14
OTIC AGENTS	NO USP CLASS	6
RESPIRATORY TRACT AGENTS	ANTI-INFLAMMATORIES, INHALED CORTICOSTEROIDS	6
RESPIRATORY TRACT AGENTS	ANTIHISTAMINES	11
RESPIRATORY TRACT AGENTS	ANTILEUKOTRIENES	3
RESPIRATORY TRACT AGENTS	BRONCHODILATORS, ANTICHOLINERGIC	2
RESPIRATORY TRACT AGENTS	BRONCHODILATORS, PHOSPHODIESTERASE INHIBITORS (XANTHINES)	3
RESPIRATORY TRACT AGENTS	BRONCHODILATORS, SYMPATHOMIMETIC	10
RESPIRATORY TRACT AGENTS	MAST CELL STABILIZERS	1
RESPIRATORY TRACT AGENTS	PULMONARY ANTIHYPERTENSIVES	6
RESPIRATORY TRACT AGENTS	RESPIRATORY TRACT AGENTS, OTHER	5
SKELETAL MUSCLE RELAXANTS	NO USP CLASS	6
SLEEP DISORDER AGENTS	GABA RECEPTOR MODULATORS	3
SLEEP DISORDER AGENTS	SLEEP DISORDERS, OTHER	5
THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES	ELECTROLYTE/MINERAL MODIFIERS	7
THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES	ELECTROLYTE/MINERAL REPLACEMENT	11